Login / Signup

The edoxaban-M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma.

Romain SiriezHalil YildizCéline BouvyHélène HaguetVincent MaloteauMichaël HardyFrançois MullierJean-Michel DognéPhilippe HainautJonathan Douxfils
Published in: Research and practice in thrombosis and haemostasis (2022)
Edoxaban and M4 do not similarly impact chromogenic assays, leading to biased chromogenic estimations of ponderal concentrations. In patient samples, this impact is even more important at low concentrations or in the case of an increase in the M4/edoxaban ratio because of hepatic or renal impairments or in case of drug interactions. This study highlights the limitations and risks of error of expressing results in ponderal concentrations instead of global activity anti-Xa.
Keyphrases
  • venous thromboembolism
  • high throughput
  • case report
  • risk assessment
  • human health
  • single cell
  • wild type